Previous 10 | Next 10 |
2024-05-26 02:45:00 ET Summary Jiangsu Hengrui Medicine out-licenses global rights for its GLP-1 candidates to US startup Hercules in a deal worth up to $6 billion. Shanghai Degron Therapeutics partners with Takeda to identify multiple targets in oncology, neuroscience, and inflam...
New network meta-analysis demonstrates favorable progression-free survival for patients treated with BRUKINSA vs other BTKi's Analysis of Kaiser Permanente database shows BRUKINSA effective and generally well tolerated, including in patients switching to BRUKINSA from ibrutinib ...
Study evaluating BRUKINSA ® in combination with venetoclax in high-risk, treatment-naïve CLL/SLL patients to be shared as oral presentation BCL2 inhibitor sonrotoclax subject of multiple presentations highlighting promising safety and efficacy as monotherapy and in c...
2024-05-13 10:58:13 ET Summary LPTX is developing DKN-01, a drug with potential in multiple types of cancer, including colorectal, esophagogastric, and endometrial cancer. LPTX's DisTinGuish study looks at DKN-01 in gastric cancer and gastroesophageal cancer patients. Part C of th...
2024-05-13 07:58:54 ET Merck ( NYSE: MRK ) has discontinued the vibostolimab and pembrolizumab coformulation arm of a late-stage skin cancer trial .... Read the full article on Seeking Alpha For further details see: Merck discontinues testing of experimental skin...
2024-05-08 13:54:43 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips BeiGene (NASDAQ: BGNE ) just reported results for the first quarter of 2024. BeiGene reported earnings per share of -$2.41. This was above the analyst estimate for EPS of ...
2024-05-08 06:16:40 ET More on BeiGene BeiGene Still Bleeding Red Ink Despite Blockbuster Drug BeiGene, AbbVie patent spat to get trial from USPTO appeals board EU regulators approve BeiGene's tislelizumab for lung cancer Seeking Alpha’s Quant Rating o...
Total revenues of $752 million in the first quarter, including product revenue of $747 million, an 82% increase from the prior-year period BRUKINSA revenue of $489 million, driven by growth in the U.S. and Europe of 153% and 243%, respectively, from the prior-year period; with recent fift...
Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...
2024-05-01 16:12:21 ET More on AbbVie, BeiGene AbbVie: The Inevitable Is Happening Unveiling AbbVie's Winning Strategy In Pharmaceutical Innovation (Rating Upgrade) BeiGene Still Bleeding Red Ink Despite Blockbuster Drug AbbVie stock slides 6% amid concer...
News, Short Squeeze, Breakout and More Instantly...
Arm D of SEQUOIA study evaluated treatment-naïve patients with high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma with del(17p) and/or TP53 mutation Preliminary data suggest promising efficacy and tolerability Safety profile was consistent with results o...
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, and NewBridge Pharmaceuticals have jointly decided to conclude their partnership. This strategic decision aligns with BeiGene’s goals to expand its presence and directly manage operations in the MENA region. T...
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the Company will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024 with a fireside chat at 1:20 pm EDT. Live webcast of this event can be acce...